Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) reduces the risk of severe neutropenia associated with chemotherapy, but its cost implications following chemotherapy are unknown. OBJECTIVE: Our objective was to examine associations between G-CSF use and medical costs after initial adjuvan...
Main Authors: | Griffiths, R, Barron, R, Gleeson, M, Danese, MD, O'Hagan, A, Chia, V, Legg, J, Lyman, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia
by: Lucky L. Shokane, et al.
Published: (2023-03-01) -
A COMBINATION OF TAXOTERE, DOXORUBICIN, CYCLOPHOSPHOMIDE IN ADJUVANT CHEMOTHERAPY OF OPERABLE BREAST CANCER GRANULOCYTE COLONY-STIMULATING FACTORS PRIMARY PROPHYLAXIS
by: N. S. Besova, et al.
Published: (2014-09-01) -
Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
by: Griffiths, R, et al.
Published: (2012) -
Study of the adjuvant properties of preparations containing recombinant human granulocyte-macrophage colony stimulating factor
by: T. I. Esina, et al.
Published: (2023-06-01) -
Granulocyte colony-stimulating factor and leukemogenesis
by: Lorena Lobo de Figueiredo, et al.
Published: (2004-01-01)